PTCT · Ptc Therapeutics, Inc.
$71.81
-0.88 (-1.21%)
At close · Aug 27
Market Cap
$6.07B
Shares
83.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$71.81
Open$72.11
Day$70.91–72.66
52W close$49.33–89.55
Avg vol 30d1.1M
Short int10.2M · 12.2% float · 10.8d
Short vol66%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 20, 2026
Est · unconfirmed
· in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−7%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
56%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+14%
trailing
YTD return
−5%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $77 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +76 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.25% of float · ▼ -3.3% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
382 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
EPS growth
+264%
Y/Y
Free cash flow
$702.3M
Balance sheet
$412.6M
net cash
Quant / Vol
risk profile
Volatility
41%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Product revenue
· 2026 full-year
$750M – $850M
Total revenue
· 2026 full-year
$1.08B – $1.18B
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
2025 full-year revenue
· 2025 full-year
$750M – $800M
Guided vs delivered
· last 3 settled
Total revenue
2024
guided $600M – $680M
$806.78M
Beat +26.1%
Total revenue
2023
guided $940M – $1B
$937.82M
Miss −3.3%
Total revenues
full year 2022
guided $710M – $750M
$698.8M
Miss −4.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−7%
Bearish
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
56%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $77 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +76 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.25% of float · ▼ -3.3% MoM · 10.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
382 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $49
Now $72 · 56%
Range high $90
vs 200-day avg -2%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP R&D expenses non-GAAP | $88.6M | Q2 2026 | — |
|
|
|||
| Non-GAAP SG&A expenses non-GAAP | $67.9M | Q2 2026 | — |
|
|
|||
| Cash, cash equivalents, and marketable securities | $1.89B | as of March 31, 2026 | — |
| Patient start forms per month in the US | 140 | first quarter of 2026 | — |
| Total patients on commercial therapy worldwide | 1,244 | as of March 31, 2026 | — |
| patient start forms received in the US | 1,134 | as of December 31, 2025 | — |
| Sephience ex-US Q4 2025 net revenue | $10.9M | Q4 2025 | — |
| Sephience Q4 2025 net revenue | $92.5M | Q4 2025 | — |
| Sephience US Q4 2025 net revenue | $81.6M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTCT
this stock
Ptc Therapeutics, Inc.
|
$6.07B | -5.5% | +36.2% | — | 12.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +4.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTCT | +1.8% | -4.9% | +14.3% | +5.6% | -5.5% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +0.7% | -8.9% | -0.4% | +2.4% | -18.5% |
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
308 filings
306 filers
Visit website
Investor relations